Nanotechnology Now - Press Release: "AMAG Pharmaceuticals, Inc. to Host Quarterly Earnings Conference Call to Discuss December 31, 2007 Results"

Home > Press > AMAG Pharmaceuticals, Inc. to Host Quarterly Earnings Conference Call to Discuss December 31, 2007 Results

Abstract:
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report financial results for the quarter and year ended December 31, 2007 after the U.S. financial markets close on Thursday, February 21, 2008. The announcement will be followed by a conference call at 4:30 p.m. ET during which management will discuss the company's financial results, quarterly highlights and the status of its development programs.

AMAG Pharmaceuticals, Inc. to Host Quarterly Earnings Conference Call to Discuss December 31, 2007 Results

Cambridge, MA | Posted on February 14th, 2008

To access the conference call via telephone, please dial (877) 412-6083 from the United States or (706) 902-1303 for international access. A telephone replay will be available from approximately 7:30 p.m. ET on February 21, 2008 through February 23, 2008. To access a replay of the conference call, dial (800) 642-1687 from the United States or (706) 645-9291 for international access. The passcode for the live call and replay is 34933555.

An audio webcast of the call will be available through the Investors section of the Company's website at www.amagpharma.com. The webcast replay will be available from approximately 7:30 p.m. ET on February 21, 2008 through March 21, 2008.

####

About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Ferumoxytol, the company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients. The company has completed enrollment in four Phase III clinical trials with ferumoxytol and has presented data on all four trials. The Company submitted a New Drug Application with the FDA in December 2007.

The company has two commercial products, Feridex I.V.® and GastroMARK®, both of which are imaging agents that are approved and marketed in the United States, Europe and other countries.

For more information, please click here

Contacts:
AMAG Pharmaceuticals, Inc.
Carol Miceli
617-498-3361

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: